ClinicalTrials.gg
CompletedNCT06174779Updated Jul 7, 2026

A Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes Mellitus

A Phase 3 interventional study of HM11260C and Placebo in Obesity, sponsored by Hanmi Pharmaceutical Company Limited. Completed at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-07-07.

Sponsored by Hanmi Pharmaceutical Company Limited · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
448
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 137 studies in Obesity with a site in Korea, Republic of — 35 open to participants now, 46 under way, 27 of them phase 3. Obesity · Korea, Republic of.

Enrollment
36th of 117
448 · median 120
Started
2024
with 4 others
Phase 3
45 of 137
19 open now
Registered
98th of 137
by date

Among the 137 studies in Obesity with a site in Korea, Republic of, this one is the 36th largest by enrollment of the 117 interventional ones that give a count, is one of 5 that started in 2024, is one of 45 in phase 3, and was the 98th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

35 of the 137 studies in Obesity with a site in Korea, Republic of are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 137 studies in Obesity with a site in Korea, Republic of, or all of them as a file.
02

Study summary

A multicenter, randomized, double-blind, phase 3 study to evaluate efficacy and safety of HM11260C in adult obesity patients without diabetes mellitus

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with following criteria :

    • ≥ 30 kg/m2 or
    • 27 kg/m2 ≤ BMI \< 30 kg/m2 with more than one risk factors or comorbidities(hypertension, dyslipidemia, sleep apnea, cardiocerebrovascular disease)
  2. A person who have failed at least once to weight control using diet and exercise therapy before screening visit.

Exclusion criteria

Exclusion Criteria:

  1. A person whose weight change exceeds 5kg within 3 months prior to screening visit.
  2. Diabetes mellitus (Type 1, type 2, etc.) or ≥ 6.5 %.
  3. Administration of hypoglycemic agents.
  4. Administration of medicines inducing weight gain.
  5. Prader-Willi Syndrome or MC4R deficiency.
  6. Cushing's Syndrome.
  7. Administration of medicines for weight management.
  8. A person who has a history of surgery(including device-based therapy) related to obesity or who has a plan during the clinical trial period.
  9. Administration of for the systemic use.
  10. gastric emptying abnormalities.
  11. History(including family history) of medullary thyroid carcinoma or multiple endocrine adenomatosis.
  12. History of acute or chronic pancreatitis.
  13. A person who has the following clinical laboratory test results :

    • TSH \< 0.4 mIU/L or TSH > 6 mIU/L
    • Calcitonin > 100 ng/L
    • Amylase or Lipase > 3 x UNL
  14. Severe liver disease ( or AST > 3 x UNL or Total > 1.5 x UNL).
  15. Severe renal disease ( \< 30mL/min/1.73m 2 ).
  16. > 450 ms.
  17. Answered 'yes' to question 4 or 5 of the suicidal ideation domain in C-SSRS or history of suicide attempt.
  18. PHQ-9 ≥ 15 or history of depression, anxiety, and other severe Mental illness.
  19. History of alcohol addiction or drug abuse.
  20. History of malignant tumors.
  21. History of severe heart disease or severe neurovascular disease.
  22. to products or multi-drug allergy.
  23. Positive to pregnancy test, nursing mother, intention on pregnancy.
  24. Considered by investigator as not appropriate to participate in the clinical study with other reason.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
448 participants (actual)

Study arms

  • Experimental
    HM11260C

    Weekly administration by subcutaneous injection

    Drug: HM11260C

  • Placebo comparator
    Placebo

    Weekly administration by subcutaneous injection

    Drug: Placebo

Interventions

  • Test drug

  • DrugPlacebo

    Placebo drug

06

What researchers measure

Primary outcomes

  1. The percent change of body weight from baseline

    Time frame: baseline, 40 weeks

  2. The proportion of subjects achieving body weight loss ≥ 5% from baseline

    Time frame: baseline, 40 weeks

Secondary outcomes

  1. The percent change of body weight from baseline

    Time frame: baseline, 24 weeks, 64 weeks

  2. The proportion of subjects achieving body weight loss ≥ 5% from baseline

    Time frame: baseline, 24 weeks, 64 weeks

  3. The proportion of subjects achieving body weight loss ≥ 10% from baseline

    Time frame: baseline, 24 weeks, 40 weeks, 64 weeks

  4. Change of body weight from baseline

    Time frame: baseline, 24 weeks, 40 weeks, 64 weeks

  5. Change of BMI from baseline

    Time frame: baseline, 24 weeks, 40 weeks, 64 weeks

  6. Change of waist circumference from baseline

    Time frame: baseline, 24 weeks, 40 weeks, 64 weeks

  7. Change of glucose metabolism parameters from baseline

    Time frame: baseline, 24 weeks, 40 weeks, 64 weeks

  8. The percentage change of lipid profile parameters from baseline

    Time frame: baseline, 24 weeks, 40 weeks, 64 weeks

  9. Change of blood pressure from baseline

    Time frame: baseline, 24 weeks, 40 weeks, 64 weeks

  10. Change of IWQoL-Lite-CT(Physical function domain) from baseline

    Time frame: baseline, 24 weeks, 40 weeks, 64 weeks

07

Study locations

1 site
  • Kangbuk samsung hospital
    Seoul, South Korea
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Aug 2025, 19 months.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 19 months is close to that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2023
First posted
Dec 18, 2023
StartActual
Jan 3, 2024
Primary completionActual
Aug 14, 2025
CompletionActual
Mar 13, 2026
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06174779
Responsible party
Sponsor
First posted
Dec 18, 2023
Start date
Jan 3, 2024
Primary completion
Aug 14, 2025
Completion
Mar 13, 2026
Last update
Jul 7, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efpeglenatide

Start the discussion